December 21, 2015
Earlier this month, Republican presidential candidate Sen. Ted Cruz (TX) and Sen. Mike Lee (R-Utah) introduced a new bill seeking to overhaul FDA operations and make it easier to introduce drugs and devices into the marketplace.
The “Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act” (or RESULT Act) would make three major changes:
While Sen. Cruz says the proposed changes will “unleash life-saving drugs and devices in the United States,” former FDA official and FDA Group consultant Larry Stevens revealed some major shortcomings of the ideas in a recent article published by the Regulatory Affairs Professionals Society.
According to Stevens, while the changes sound good on the surface, they ignore some major issues when looked at from a practical perspective.
To Stevens, the problem with the reciprocal approval of drugs from other countries is simple:
“No developed country has the expertise to review a product like the FDA does.”
If the bill became law, companies would simply seek approval from countries with the lowest standards and then wait on word from the FDA. Even with 30 days to act, however, Stevens is confident the FDA would still reject nearly every application, leaving companies in the same place they started.
Stevens offered Thalidomide as a real-world example of the problem. While the drug was approved in Europe, it would later be shown to lead to birth defects, an outcome the FDA prevented in the U.S. by denying the application despite European approval.
With the ability to override an FDA denial in Congress, Stevens warns we’d be relying on emotion rather than scientific evidence to decide which drugs enter the market.
“FDA gets rid of the emotion,” he said, adding if Congress did override an FDA decision, it would leave congressmen responsible for the drug or device’s safety.
Although the bill is highly unlikely to receive President Obama’s signature, the proposal may breathe new life into the conversation around FDA reform which started with 21st Century Cures Act.
Want to learn more about the FDA’s current expedited approval programs? Grab our free whitepaper: New Drug Applications: What You Should Know.
Proprietary talent selection of former FDA & Industry Experts amplified by a corporate culture of responsiveness & execution.
The FDA Group will not be liable for any errors or omissions in this information nor for the availability of this information. The owner will not be liable for any losses, injuries, or damages from the display or use of this information.